XML 66 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Product Revenue Reserves and Allowances - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 17, 2020
Mar. 31, 2013
Aug. 31, 2020
Feb. 29, 2020
Jan. 31, 2020
Aug. 31, 2019
Nov. 30, 2018
Dec. 31, 2021
Dec. 31, 2020
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               $ 36,939,000 $ 34,437,000
Icon Bioscience Inc [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Sales-based royalty expense               0 $ 1,300,000
Percentage of accelerated milestone payment received                 20.00%
Amended Alimera Science Inc Agreement [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               54,000 $ 1,700,000
OncoSil Medical UK Limited [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               0  
Deferred revenue               $ 100,000 100,000
Receipt of upfront license fee   $ 100,000              
Royalty percentage earned from sales of product               8.00%  
Percentage of non-royalty consideration received from sublicense               20.00%  
License agreement commencement date               2012-12  
Ocumension Therapeutics [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Deferred revenue               $ 0 $ 0
Receipt of upfront license fee     $ 9,500,000 $ 2,000,000.0     $ 1,750,000    
Potential future payments based on achievement of development and regulatory milestones     6,000,000.0   $ 6,000,000.0     7,250,000  
Potential future payments based on achievement of commercial-based milestones     6,000,000.0   $ 6,000,000.0     3,000,000.0  
Development milestone payment received           $ 1,000,000.0      
Potential future payments based on achievement of combined remaining development and sales milestone     11,750,000            
Potential future payments based on achievement of remaining development and regulatory milestones     6,250,000            
Potential future payments based on achievement of remaining commercial-based milestones     3,000,000.0            
Ocumension Therapeutics [Member] | Share Offering [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Issuance of stock, net of issue costs, shares                 3,010,722
Ocumension Therapeutics [Member] | Maximum [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Product supply milestones and development milestones               7,250,000  
Upon achievement of milestones     $ 21,250,000            
Royalty Income [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               871,000 $ 1,664,000
Royalty Income [Member] | Amended Alimera Science Inc Agreement [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               0 1,700,000
RPA [Member] | SWK [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               872,000 0
Upfront cash payment $ 16,500,000                
Royalty payments               2,800,000  
Royalty Sale Agreement [Member] | SWK [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Deferred revenue $ 16,500,000                
Deferred revenue, current               1,100,000 885,000
Deferred revenue, non-current               14,600,000 15,600,000
Collaborative Research and Development [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               60,000 255,000
Deferred revenue               0 60,000
Collaborative Research and Development [Member] | OncoSil Medical UK Limited [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               100,000  
License and Collaboration Agreement [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               756,000 11,942,000
License and Collaboration Agreement [Member] | Ocumension Therapeutics [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               543,000 11,500,000
Product [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               35,312,000 20,831,000
Product [Member] | Ocumension Therapeutics [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               308,000 213,000
Technical Assistance [Member] | Ocumension Therapeutics [Member]                  
Disclosure of Product Revenue Reserves and Allowances [Line Items]                  
Revenue               $ 499,000 $ 0